insulin 338 (GIPET I)

DRUG4 trials

Sponsors

Novo Nordisk A/S

Conditions

DiabetesDiabetes Mellitus, Type 2Healthy

Phase 1

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

CompletedNCT01796366

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 2

Start: 2013-02-21End: 2013-08-19Updated: 2017-03-01

A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects

CompletedNCT01931137

Novo Nordisk A/SDiabetes, Healthy

Start: 2013-08-31End: 2013-12-31Updated: 2014-01-06

Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects

CompletedNCT02304627

Novo Nordisk A/SDiabetes, Healthy

Start: 2014-11-24End: 2015-07-31Updated: 2019-07-08

Phase 2

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

CompletedNCT02470039

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 2

Start: 2015-06-01End: 2015-12-31Updated: 2019-03-18

Related Papers

The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects

Clinical Pharmacokinetics2019-05-1634 citations

Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.

2019-01-21115 citations